Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Total Liabilities for 16 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 3.99% to $46.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Dec 2025, down 3.99% year-over-year, with the annual reading at $46.8 million for FY2025, 3.99% down from the prior year.
  • Total Liabilities for Q4 2025 was $46.8 million at Anika Therapeutics, up from $42.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $85.6 million in Q1 2021, with the low at $40.0 million in Q2 2025.
  • Average Total Liabilities over 5 years is $57.4 million, with a median of $57.1 million recorded in 2022.
  • The sharpest move saw Total Liabilities plummeted 52.33% in 2021, then increased 8.92% in 2023.
  • Over 5 years, Total Liabilities stood at $60.4 million in 2021, then increased by 5.15% to $63.6 million in 2022, then fell by 8.18% to $58.4 million in 2023, then dropped by 16.48% to $48.8 million in 2024, then decreased by 3.99% to $46.8 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $46.8 million, $42.6 million, and $40.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.